Kopfschmerz bei Medikamentenübergebrauch

Zusammenfassung

Der Kopfschmerz durch Medikamentenübergebrauch (MOH) ist eine weltweit verbreitete und beeinträchtigende Erkrankung, die durch übermäßige Einnahme von Akuttherapie entsteht und die Lebensqualität erheblich beeinträchtigen kann und das obwohl z.B. einfache Informationen über Ursachen und Folgen der Erkrankung dazu beitragen können, den MOH zu verhindern oder zu beenden. In den letzten Jahren konnten viele neue Erkenntnisse zum Kopfschmerz durch Medikamentenübergebrauch generiert werden. Zudem haben sich die Diagnosekriterien und die Leitlinienempfehlungen umfassend gewandelt. Dieser Artikel bietet einen umfassenden Überblick über die Klinik, Definition/Klassifikation, Epidemiologie, Risikofaktoren, Pathophysiologie, Kontroversen, Prävention und Behandlung des MOH.

Abstract

Medication overuse headache (MOH) is a globally prevalent and debilitating condition that results from excessive use of acute therapies and can significantly affect quality of life, despite the fact that simple information about the causes and consequences of the condition can help prevent or stop MOH. In recent years, many new insights have been gained into headaches caused by medication overuse. In addition, the diagnostic criteria and guideline recommendations have changed considerably. This article provides a comprehensive overview of the clinic, definition/classification, epidemiology, risk factors, pathophysiology, controversies, prevention, and treatment of MOH.

Schlüsselwörter

Chronischer Kopfschmerz - Kopfschmerz bei Medikamentenübergebrauch - Migräne - MÜKS - Kopfschmerz vom Spannungstyp

Keywords

Chronic headache - Medication-overuse headache - Migraine - Tension-type headache (TTH) - MOH

Publikationsverlauf

Eingereicht: 20. November 2023

Angenommen nach Revision: 15. Mai 2024

Artikel online veröffentlicht:
18. Juli 2024

• Literatur

• 1 Horton BT, Peters GA. Clinical manifestations of excessive use of ergotamine preparations and mangement of withdrawal effect: report of 52 cases. Headache 1963; 2: 214-227
• 2 Jellestad PL, Carlsen LN, Westergaard ML. et al. Economic benefits of treating medication-overuse headache – results from the multicenter COMOESTAS project. Cephalalgia 2019; 39: 274-285
• 3 Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2^nd edition. Cephalalgia. 2004. 24. 9-160
• 4 Olesen J, Bousser M-G, Diener H-C. et al. New appendix criteria open for a broader concept of chronic migraine. Cephalalgia 2006; 26: 742-746
• 5 Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3^rd edition. Cephalalgia. 2018. 38. 1-211
• 6 Grande RB, Aaseth K, Benth JŠ. et al. Reduction in medication-overuse headache after short information. The Akershus study of chronic headache. Eur J Neurol 2011; 18: 129-137
• 7 Créac’h C, Radat F, Mick G. et al. One or several types of triptan overuse headaches?. Headache 2009; 49: 519-528
• 8 Limmroth V, Katsarava Z, Fritsche G. et al. Features of medication overuse headache following overuse of different acute headache drugs. Neurology 2002; 59: 1011-1014
• 9 Thorlund K, Sun-Edelstein C, Druyts E. et al. Risk of medication overuse headache across classes of treatments for acute migraine. J Headache Pain 2016; 17: 107
• 10 Bigal ME, Lipton RB. Excessive acute migraine medication use and migraine progression. Neurology 2008; 71: 1821-1828
• 11 Hagen K, Linde M, Steiner TJ. et al. Risk factors for medication-overuse headache: an 11-year follow-up study. The Nord-Trøndelag Health Studies. Pain 2012; 153: 56-61
• 12 Reuter U, Salomone S, Ickenstein GW. et al. Effects of chronic sumatriptan and zolmitriptan treatment on 5-HT receptor expression and function in rats. Cephalalgia 2004; 24: 398-407
• 13 De Felice M, Ossipov MH, Wang R. et al. Triptan-induced enhancement of neuronal nitric oxide synthase in trigeminal ganglion dural afferents underlies increased responsiveness to potential migraine triggers. Brain 2010; 133: 2475-2488
• 14 Ayzenberg I, Obermann M, Nyhuis P. et al. Central sensitization of the trigeminal and somatic nociceptive systems in medication overuse headache mainly involves cerebral supraspinal structures. Cephalalgia 2006; 26: 1106-1114
• 15 Vos T, Barber RM, Bell B. et al. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015; 386: 743-800
• 16 Stovner LJ, Andree C. Prevalence of headache in Europe: a review for the Eurolight project. J Headache Pain 2010; 11: 289-299
• 17 Castillo J, Muñoz P, Guitera V. et al. Kaplan Award 1998. Epidemiology of chronic daily headache in the general population. Headache: The Journal of Head and Face Pain 1999; 39: 190-196
• 18 Lantéri-Minet M, Auray J-P, El Hasnaoui A. et al. Prevalence and description of chronic daily headache in the general population in France. Pain 2003; 102: 143-149
• 19 Straube A, Pfaffenrath V, Ladwig K-H. et al. Prevalence of chronic migraine and medication overuse headache in Germany – the German DMKG headache study. Cephalalgia 2010; 30: 207-213
• 20 Porst M, Wengler A, Leddin J. et al. Migräne und Spannungskopfschmerz in Deutschland. Prävalenz und Erkrankungsschwere im Rahmen der Krankheitslast-Studie BURDEN 2020 2020;
• 21 Meskunas CA, Tepper SJ, Rapoport AM. et al. Medications Associated with Probable Medication Overuse Headache Reported in a Tertiary Care Headache Center Over a 15-Year Period. Headache: The Journal of Head and Face Pain 2006; 46: 766-772
• 22 Fritsche G, Frettlöh J, Hüppe M. et al. Prevention of medication overuse in patients with migraine. Pain 2010; 151: 404-413
• 23 Hedenrud T, Babic N, Jonsson P. Medication overuse headache: self-perceived and actual knowledge among pharmacy staff. Headache 2014; 54: 1019-1025
• 24 Do TP, Remmers A, Schytz HW. et al. Red and orange flags for secondary headaches in clinical practice: SNNOOP10 list. Neurology 2019; 92: 134-144
• 25 Heinze A. et al. Neues aus der Akuttherapie der Migräne. Fortschr Neurol Psychiatr 2024;
• 26 Katsarava Z, Fritsche G, Muessig M. et al. Clinical features of withdrawal headache following overuse of triptans and other headache drugs. Neurology 2001; 57: 1694-1698
• 27 Baumgartner C, Wessely P, Bingöl C. et al. Longterm Prognosis of Analgesic Withdrawal in Patients with Drug-Induced Headaches. Headache: The Journal of Head and Face Pain 1989; 29: 510-514
• 28 Diener HC, Dichgans J, Scholz E. et al. Analgesic-induced chronic headache: long-term results of withdrawal therapy. J Neurol 1989; 236: 9-14
• 29 Schnider P, Aull S, Baumgartner C. et al Long-term outcome of patients with headache and drug abuse after inpatient withdrawal: five-year follow-up. Cephalalgia 1996; 16: 481-485 discussion 461
• 30 Grazzi L, Andrasik F, D’Amico D. et al. Behavioral and pharmacologic treatment of transformed migraine with analgesic overuse: outcome at 3 years. Headache 2002; 42: 483-490
• 31 Williams DR, Stark RJ. Intravenous lignocaine (lidocaine) infusion for the treatment of chronic daily headache with substantial medication overuse. Cephalalgia 2003; 23: 963-971
• 32 Zidverc-Trajkovic J, Pekmezovic T, Jovanovic Z. et al. Medication overuse headache: clinical features predicting treatment outcome at 1-year follow-up. Cephalalgia 2007; 27: 1219-1225
• 33 Tfelt-Hansen P, Krabbe A. Ergotamine abuse. Do patients benefit from withdrawal?. Cephalalgia 1981; 1: 29-32
• 34 Pini LA, Cicero AF, Sandrini M. Long-term follow-up of patients treated for chronic headache with analgesic overuse. Cephalalgia 2001; 21: 878-883
• 35 Raggi A, Giovannetti AM, Leonardi M. et al. Predictors of 12-Months Relapse After Withdrawal Treatment in Hospitalized Patients With Chronic Migraine Associated With Medication Overuse: A Longitudinal Observational Study. Headache 2017; 57: 60-70
• 36 Chiang C-C, Schwedt TJ, Wang S-J. et al. Treatment of medication-overuse headache: A systematic review. Cephalalgia 2016; 36: 371-386
• 37 Katsarava Z, Muessig M, Dzagnidze A. et al. Medication overuse headache: rates and predictors for relapse in a 4-year prospective study. Cephalalgia 2005; 25: 12-15
• 38 Carlsen LN, Munksgaard SB, Jensen RH. et al. Complete detoxification is the most effective treatment of medication-overuse headache: A randomized controlled open-label trial. Cephalalgia 2018; 38: 225-236
• 39 Krymchantowski AV, Tepper SJ, Jevoux C. et al. Medication-Overuse Headache: Protocols and Outcomes in 149 Consecutive Patients in a Tertiary Brazilian Headache Center. Headache 2017; 57: 87-96
• 40 Lo Castro F, Guerzoni S, Pellesi L. Safety and Risk of Medication Overuse Headache in Lasmiditan and Second-Generation Gepants: A Rapid Review. Drug Healthc Patient Saf 2021; 13: 233-240
• 41 Navratilova E, Behravesh S, Oyarzo J. et al. Ubrogepant does not induce latent sensitization in a preclinical model of medication overuse headache. Cephalalgia 2020; 40: 892-902
• 42 Saengjaroentham C, Strother LC, Dripps I. et al. Differential medication overuse risk of novel anti-migraine therapeutics. Brain 2020; 143: 2681-2688